指南与共识皮肤肿瘤

皮肤黑色素瘤的早期检测与预后评估:最佳实践共识及基因表达谱检测的作用

Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing.
指南 / 共识 · JAMA Dermatol · 2023-01-01

该共识采用改良Delphi法,邀请60名黑色素瘤专家小组参与,经邮件调查(n=42)、共识会议(n=51)和后续调查(n=45),就皮肤黑色素瘤筛查、色素性皮损评估工具及基因表达谱检测的应用达成共识建议。专家小组支持风险分层筛查方法,认为视觉检查和皮肤镜检查足以评估无害的黑色素细胞皮损,但对基因表达谱检测在临床决策中的明确作用未达成共识。

要点

  • 专家小组支持在临床和公共筛查中采用风险分层方法进行黑色素瘤筛查。
  • 视觉检查和皮肤镜检查足以评估和随访被认为无害的黑色素细胞皮损。
  • 低风险预后基因表达谱评分不应凌驾于令人担忧的组织学特征之上来决定是否进行前哨淋巴结活检。

核心结论

  • 专家小组就黑色素瘤筛查和随访的风险分层方法以及视觉检查和皮肤镜的使用达成共识,这些发现支持一种诊断和评估皮肤黑色素瘤的实用方法。
  • 专家小组未就基因表达谱检测在临床决策中的明确作用达成共识,认为需要额外研究来确立现有基因表达谱检测的临床用途。

研究设计与样本

  • 采用改良Delphi共识方法,邀请60名黑色素瘤专家小组成员参与。
  • 通过电子邮件调查(n=42)对假设场景进行投票,随后召开共识会议(n=51)审查文献和调查答案的理由。
  • 专家小组成员参与后续调查(n=45)以形成对场景的最终建议。

主要发现

  • 专家小组达成共识(≥70%一致)支持在临床环境和公共筛查活动中采用风险分层的黑色素瘤筛查方法。
  • 专家小组就筛查人员建议(自我/伴侣、初级保健提供者、普通皮肤科医生和色素性皮损专家)、筛查间隔和可接受的预约等待时间达成共识。
  • 参与者达成共识,视觉和皮肤镜检查足以评估和随访被认为无害的黑色素细胞皮肤皮损。
  • 专家小组就解读反射式共聚焦显微镜和部分但非全部表皮胶带剥离结果达成共识,但未就使用某些色素性皮损评估工具(如电阻抗光谱)达成共识。
  • 关于基因表达谱评分,专家小组达成共识,在选择患者进行前哨淋巴结活检时,低风险预后基因表达谱评分不应凌驾于令人担忧的组织学特征之上,但未就高风险预后基因表达谱评分且低风险组织学和/或淋巴结状态阴性情况下的影像学建议达成共识。

关键数值与推荐

  • 共识阈值定义为≥70%一致。
  • 支持风险分层的黑色素瘤筛查方法(临床环境和公共筛查活动)。
  • 筛查人员建议包括自我/伴侣、初级保健提供者、普通皮肤科医生和色素性皮损专家。
  • 视觉和皮肤镜检查足以评估和随访被认为无害的黑色素细胞皮肤皮损。
  • 低风险预后基因表达谱评分不应凌驾于令人担忧的组织学特征之上来决定是否进行前哨淋巴结活检。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 专家小组未就基因表达谱检测在临床决策中的明确作用达成共识。
  • 专家小组认为需要额外研究来确立现有基因表达谱检测的临床用途。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Therapy for advanced melanoma has transformed during the past decade, but early detection and prognostic assessment of cutaneous melanoma (CM) remain paramount goals. Best practices for screening and use of pigmented lesion evaluation tools and gene expression profile (GEP) testing in CM remain to be defined. OBJECTIVE: To provide consensus recommendations on optimal screening practices and prebiopsy diagnostic, postbiopsy diagnostic, and prognostic assessment of CM. EVIDENCE REVIEW: Case scenarios were interrogated using a modified Delphi consensus method. Melanoma panelists (n = 60) were invited to vote on hypothetical scenarios via an emailed survey (n = 42), which was followed by a consensus conference (n = 51) that reviewed the literature and the rationale for survey answers. Panelists participated in a follow-up survey for final recommendations on the scenarios (n = 45). FINDINGS: The panelists reached consensus (≥70% agreement) in supporting a risk-stratified approach to melanoma screening in clinical settings and public screening events, screening personnel recommendations (self/partner, primary care provider, general dermatologist, and pigmented lesion expert), screening intervals, and acceptable appointment wait times. Participants also reached consensus that visual and dermoscopic examination are sufficient for evaluation and follow-up of melanocytic skin lesions deemed innocuous. The panelists reached consensus on interpreting reflectance confocal microscopy and some but not all results from epidermal tape stripping, but they did not reach consensus on use of certain pigmented lesion evaluation tools, such as electrical impedance spectroscopy. Regarding GEP scores, the panelists reached consensus that a low-risk prognostic GEP score should not outweigh concerning histologic features when selecting patients to undergo sentinel lymph node biopsy but did not reach consensus on imaging recommendations in the setting of a high-risk prognostic GEP score and low-risk histology and/or negative nodal status. CONCLUSIONS AND RELEVANCE: For this consensus statement, panelists reached consensus on aspects of a risk-stratified approach to melanoma screening and follow-up as well as use of visual examination and dermoscopy. These findings support a practical approach to diagnosing and evaluating CM. Panelists did not reach consensus on a clearly defined role for GEP testing in clinical decision-making, citing the need for additional studies to establish the clinical use of existing GEP assays.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Kashani-Sabet M, Leachman SA, Stein JA, et al. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing. JAMA Dermatol. 2023. PMID: 36920356. doi:10.1001/jamadermatol.2023.0127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。